FDA's Ongoing User Fee System Upgrade Limits Payment Options
This article was originally published in The Pink Sheet Daily
Executive Summary
But it comes at a time when there is traditionally a lull in filings of generic drug applications.
You may also be interested in...
GDUFA II: Inspection Information Takes Center Stage
Sponsors say transparency is important as generic drug user fee negotiations move to inspection policy.
PDUFA Negotiations Begin With FDA Seeking Review System Reform
Fee structure changes and process enhancements floated during opening session between industry and agency.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.